Pharmaceutical Outcomes Research is a PhD program in the graduate program in Clinical Pharmacy. This program is housed in the Center for Pharmaceutical Outcomes Research (CePOR, SEE-por), a school-wide center in the Skaggs School of Pharmacy. Our doctoral curriculum is designed to provide competent and highly skilled researchers in the study of patient, provider, or population-level health care and health system interventions. We most often focus on economic, clinical, and humanistic outcomes such as clinical or cost effectiveness or safety. Areas of focus available to students undertaking this course of study include pharmacoeconomics, pharmacoepidemiology, health services research, and drug policy.​​​

The traditional requirements for admission to the graduate program in pharmaceutical sciences include:

  • BA or BS from an accredited institution
  • Academic record
    • Satisfying the minimum admission requirements established by the CU Graduate School
    • Normally admission dependent on GPA of 3.0 or better
    • GPA <3.0 may be considered individually on a provisional basis
  • Graduate Record Examination (GRE) results - Average scores of student admitted are approximately:
    • Verbal 500
    • Quantitative 700
    • Analytical writing 4.5

If you do not have a degree from a U.S. or Canadian institution, it is required that an outside professional evaluation of your higher education credentials be conducted. This evaluation must include an analysis of courses, grades and grade point average, and U.S. degree equivalency. Evaluations will be accepted from any reputable professional company. Three recommended credential evaluation companies are:

  • World Education Services (Highly recommended) - (request the Course by Course evaluation)
  • American Association of Collegiate Registrars and Admissions Officers (request the Course by Course evaluation)
  • International Education Research Foundation (request the "Detail Report")

The admission deadline for completed applications is December 1.

Application Information

Given that admission to the program is very competitive, it is impossible to evaluate your qualifications for admission (test scores, grades) until the selection committee assesses the entire applicant pool. If you are selected for an interview, we do our best to pay your travel expenses to and from campus. Admission to the program includes financial support via a monthly stipend. The initial process involves submitting an online application to graduate school and can be initiated by following the link on the main page.

If you live outside of North America (regardless of your nationality), you are at a disadvantage because we do not have enough resources to cover international travel expenses and therefore it is unlikely that we will cover travel costs for an interview. Conducting an interview by phone is an option, but may put you at a disadvantage compared to other candidates.

Admission to the program includes financial support via a stipend awarded on a 12-month basis. The student stipend is $27,000 per year. Based on the rules of the UCD Graduate School, all PhD students in good academic standing are guaranteed financial support.

Although a priority of the School of Pharmacy is to provide financial support to its graduate students, payment of stipend, tuition and any fees by the School of Pharmacy or by grants, contracts or gifts to the School of Pharmacy faculty is contingent upon satisfactory academic progress (as defined by the UCD Graduate School, Graduate Student Handbook) and completion of required teaching duties, core courses, research rotations, seminars, and examinations (as listed on the progress report form). The School of Pharmacy also reserves the right to review and adjust its funding policies at any time. All students are expected to work full-time toward program requirements for 12 months of the year.

Generally, the first year of financial support will be in the form of stipend support for working as a teaching assistant. Depending on availability, teaching assistantships may be offered beyond one year to students. Faculty may choose to offer research assistant scholarships to students as well. Other funding opportunities in the form of external student grants and awards also exist. Students are encouraged to talk to the faculty about funding and scholarship opportunities. Funds for travel to one meeting where students are presenting a poster or giving a podium presentation are limited to $500 per fiscal year.

Students who do not remain in good graduate standing (3.0 GPA or above) or maintain satisfactory academic progress are placed on academic probation. Probation and suspension policies are described in the UCD Graduate School, Graduate Student Handbook. Payment of stipend, tuition, insurance and fees for a student while on academic probation is at the discretion of the graduate program committee.​​

Mission:

Advance the science of pharmaceutical outcomes research by training scientists who generate and synthesize evidence to inform practice and policy.

Goal:

The goal of the PhD n pharmaceutical outcomes research is to develop methodological experts. Graduates will have the knowledge and extensive skills necessary to conduct pharmacoeconomic, pharmacoepidemiologic, health services, and drug policy research. We train individuals who can contribute to T3-T4 clinical translational pharmacy and pharmaceutical sciences, specifically on effective, population health, and policy studies. These contributions should ultimately benefit pharmacists and society with safe, effective, and efficient use of pharmaceutical care.​​

The Pharmaceutical Outcomes Research PhD program trains graduate students to become proficient and successful investigators who are able to:

  1. demonstrate an in-depth knowledge of central concepts in Pharmaceutical Outcomes Research, including the areas of pharmacoeconomics, pharmacoepidemiology, and/or drug policy.
  2. critically appraise existing literature and sources of information.
  3. formulate hypotheses based on current concepts in the field and accurately and correctly design, conduct, and interpret their own research projects.
  4. present research results in peer-reviewed publications and in a dissertation.
  5. perform research that adheres to the principles and guidelines of ethical conduct.
  6. communicate research results effectively through oral presentations at scientific seminars, conferences, and other venues

Required Courses

  
BIOS 6611/6612​Biostatistical Methods I and Biostatistical Methods II
EPID 6630Epidemiology
PHSC 7620Research Design and Methodology in Pharmaceutical Outcomes Research
HSMP 6604Health Care Economics
EPID 6631Analytical Epidemiology
PHSC 7611Pharmacoeconomics (Campbell)
PHSC 7613Pharmaceutical and Drug Related Policy (Nair)
PHSC 7615Pharmacoepidemiology (Valuck)
PHSC 7570Graduate Student Seminar
PHSC 7911Research Practicum
Total Required Core Course Credits for All Students
CLSC 8990Doctoral Thesis

Approved Elective Courses

   
BIOS 6643 Analysis of Longitudinal Data
BIOS 6646 Survival Analysis
BIOS 6648/6649 Design of Clinical Trials and Experiments (can take 6648 OR 6649)
BIOS 6649 Design of Studies in the Health Sciences
BIOS 6659 Statistical Methods in Genomics
BIOS 6680 SAS Programming for Data Analysis
BIOS 6683 Introduction to Health Information Technology
BIOS 7711-7713 Advanced Statistical Methods Courses
CBHS 6620 Survey Research
ECON 5813 Econometrics I (UCD downtown campus)
ECON 5823 Econometrics II (UCD downtown campus)
EPID 6632 Advanced Epidemiology
EPID 6646 Introduction to Systematic Reviews
EPID 6635 Epidemiology of Communicable Disease
EPID 6636 Chronic Disease Epidemiology
EPID 6638 Cardiovascular Epidemiology
EPID 6639 Genetic and Molecular Epidemiology
HSMP 6603 Health Care Systems
HSMP 6609 Cost Benefit and Effectiveness in Health
HSMP 6617 Introduction to Health Services Research
HSMP 6625 Methods in Health Services Research

The program’s strengths in outcomes research are emphasized in 35 credits of several areas:

  • Biostatistics
  • Epidemiology
  • Economics
  • Health Policy
  • Research/Study Design
  • Doctoral Thesis

The program has experience in accessing a multitude of data such as MEPS, PHARMetrics, University Health-System, Consortium and MarketScan. Students are encouraged to utilize these datasets as well as primary data collection. Students may enroll in courses not listed (e.g courses in downtown campuses and/or newly developed courses) by consulting with the program director.

Graduation Requirements and Process

The following are specific rules approved by the graduate faculty of our school for graduate studies leading to the doctor of philosophy degree in the pharmaceutical sciences. All other requirements for these degrees will follow the guidelines of the Graduate School, which can be found in the Graduate Student Handbook of the University of Colorado Anschutz Medical Campus Graduate School. The graduate student assumes primary responsibility for meeting the rules of the Skaggs School of Pharmacy and the Graduate School. Failure to meet the following rules and guidelines may result in delay of graduation.​​​

Pharmacoepidemiology

Pharmacoeconomics

Pharmaceutical and Drug Related Policy

  

Kimberly Deininger

Kimberly Deininger

Kimberly Deininger was born and raised in Cleveland, Ohio. She graduated from Case Western Reserve University with a BS in Biology in 2006. She then moved to Colorado and earned an MPH in Epidemiology from the Colorado School of Public Health in 2015. She began working with Dr. Christina Aquilante during her master’s program, studying pharmacogenomics in cardiac transplant patients. She joined the POR program in 2016 to advance her research skills and pursue her goal of improving upon medications. She feels that the faculty in this program are unparalleled, as they provide diverse research interests, opportunities, and expertise in all areas of pharmaceutical outcomes research. She continues to conduct research in Dr. Aquilante’s lab, focusing on the clinical utility of pharmacogenomics in solid organ transplantation. In her free time, Kimberly enjoys hiking in the mountains, watching live music, and traveling. LinkedIn: https://www.linkedin.com/in/kmdeininger/

Katia Hannah

Katia Hannah

Katia Hannah is a Washington State native. She graduated from Washington State University with a BS in Zoology in 2010. She then moved to Colorado to attend Colorado School of Public health, completing both the Certificate and Masters in Public Health programs with a focus in epidemiology. During the master's program, she worked with Dr. Rob Valuck and Dr. Heather Anderson on her capstone project studying the association between anticholinergic toxicity and adverse health outcomes using measures of toxicity generated by three anticholinergic toxicity scales. She joined the CePOR program in fall 2016 and is currently conducting health outcomes research focusing on Epinephrine Auto-Injectors with Dr. Robert Brett McQueen.

Chong Kim

Chong Kim (CK)

Chong Kim (CK) was born in East Lansing Michigan and spent most of his time in Michigan until he graduated in 2009 with a BS in Biochemistry from the Michigan State University. He went on to receive his MPH in Health Policy and Management from the Columbia University Mailman School of Public Health in 2013. He worked as a junior analyst in Korea, identifying cost-effective therapies for ovarian cancer and Cushing's disease, such that formulary decisions could be updated. CK started the PhD program in Pharmaceutical Outcomes Research in fall 2015 and has been interested in utilizing machine learning and statistical models to determine the impact of short-acting beta-agonist on clinical and economic outcomes of asthma patients. CK has a website featuring some of the research he's doing.

Sue Kwon

Sue Kwon

Sue Kwon is from Seoul, South Korea, and majored in Neuroscience at Pomona College. The goal of her current project is to evaluate the cost-effectiveness of multiple sclerosis (MS) disease modifying therapies (DMT) using a claims database. She hopes to advocate for health equality and support underserved communities, LGBTQ+ communities, and immigrant communities through outcomes research. Thanks to the wonderful mentorship that the CEPOR faculty offers, Sue has been able to establish a balance between research and academics her first year. In her free time, she likes to travel, cook, and spend time with friends. Pronouns: She, her, hers, Github: https://github.com/shyunk, Linkedin: https://www.linkedin.com/in/suehkwon.

Nicholas Mendola

Nicholas Mendola

 

Vanessa Patterson

Vanessa Paul Patterson

Vanessa Paul Patterson grew up in Kansas City before moving to New Orleans in 2006. She graduated from Tulane University with a BSPH in Environmental Health Sciences in 2010 and stayed on at Tulane University School of Public Health and Tropical Medicine to complete her MPH with a dual concentration in Epidemiology and Maternal and Child Health in 2012. Vanessa went on to work as an applied epidemiologist for government public health agencies for six years. Her work covered a range of topics, including environmental health, occupational health and injury, chronic diseases, and infectious diseases. Vanessa joined the Pharmaceutical Outcomes Research track in the fall of 2018. She is currently working with Dr. Melanie Whittington in support of the Data Science to Patient Value (D2V) NavLab.

Why CU's Pharmaceutical Outcomes Research PhD Program?

Chong Kim: There were several factors that ultimately led me to choose POR training program. The biggest factor was the research output from alumni. Although individual capacity may determine the amount of research that may be done, I felt that at least everyone had enough exposure to opportunities to contribute to various projects that the faculty were a part of. Another factor was the prospects for a future career. Some of the alumni graduated to take the academic route, some took on the industry route. What allowed me to be at ease of mind was the fact that none of them had difficulty in job searching and were doing quite well due to the opportunities (research and networking) they had during their stay in the program. I’ve been involved in several projects throughout my first and second semester and I know I’ve definitely made the best choice in coming to this program based on just that.

PhD Student Research Projects

  • Cost Effectiveness of New Hepatitis C Therapies
  • Associations between Antibiotic Exposure and Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Julia F. Slejko, PhD ('12)
Assistant Professor
Pharmaceutical Health Services Research
University of Maryland School of Pharmacy

R. Brett McQueen, PhD ('13)
Health Economist and Head of Statistics
Research in Real Life (RiRL)
Observational and Pragmatic Research Institute (OPRI)​

William V. Padula, PhD, MS, MSc ('13)
Assistant Professor
Department of Health Policy & Management, ​Johns Hopkins Bloomberg School of Public Health
The Armstrong Institute for Patient Quality & Safety, Johns Hopkins Medicine
Johns Hopkins School of Nursing

For questions regarding graduate school programs contact:

Jackie Milowski - 303-724-7263, Jackie.Milowski@CUAnschutz.edu​​​​​